Medicare AdvantageCoverageMedium impact
MA07.044b, Measurement of Exhaled Nitric Oxide and Breath Condensate in the Diagnosis and Management of Asthma and Other Respiratory Disorders
Independence Blue Cross·Pulmonology, Allergy & Immunology, Family Medicine +2 more·Medical Policy
Effective date
Jan 22, 2025
We identified it
Jun 19, 2026
Summary
This is a reissued Medicare Advantage policy regarding measurement of exhaled nitric oxide and breath condensate for asthma and respiratory disorder diagnosis and management, effective January 22, 2025. The policy appears to be an update to existing coverage guidelines but specific changes are not detailed in the summary provided.
Action Required
By January 22, 2025: Billing team should review the full policy document at the provided URL to understand specific coverage changes for exhaled nitric oxide testing procedures. Verify current billing practices align with updated Medicare Advantage requirements for respiratory diagnostic testing.